Clinical trial
EARLY IFNb-1a and Atorvastatin Combination Therapy of Isolated Clinical Syndrome…
NCT00137176 · University of North Carolina, Chapel Hill, Other · Completed
Key facts
| NCT number | NCT00137176 |
|---|---|
| Title | EARLY IFNb-1a and Atorvastatin Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis |
| Official title | EARLY IFNb-1a (Rebif) and Atorvastatin (Lipitor) Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis |
| Lead sponsor | University of North Carolina, Chapel Hill, Other |
| Status | Completed |
| Study type | Interventional |
| Conditions | Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | Rebif |
| Enrollment | 30 |
| Start date | Oct 1, 2004 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2008 |
| First posted | Aug 29, 2005 |
| Last update posted | Jun 23, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: